|
|
|
|
|
|
- TG4050 is being evaluated in two Phase 1 clinical trials. It combines Transgene's proprietary myvac platform with NEC's cutting-edge Artificial Intelligence (AI) capabilities to select patient-specific neoantigens
- Data confirm that the prediction algorithm successfully identifies immunogenic cancer mutations, even among a large set of candidate mutations
- Data will be presented at upcoming Virtual AACR 2020 Session II |
TOKYO, May 15, 2020 - (JCN Newswire) - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (TSE: 6701), a leader in IT and network technologies, today announce that they will present data demonstrating that the prediction algorithm used to customize TG4050 for each patient is accurate at identifying immunogenic cancer mutations even among a large set of candidate mutations. These data were jointly generated by the Transgene, NEC and NEC Laboratories Europe GmbH teams and will be presented at the upcoming meeting of the American Association for Cancer Research (AACR) Annual Meeting 2020 (AACR Virtual Annual Meeting II).
TG4050 is an individualized therapeutic vaccine based on Transgene's myvac technology. It is powered by NEC's cutting-edge AI capabilities. Two Phase 1 trials with TG4050 are ongoing in Europe and in the USA.
TG4050 has been designed to target up to 30 patient-specific neoantigens (cancer cell mutations) which are selected using NEC's Neoantigen Prediction System, an advanced AI technology that has already been applied in the field of oncology. The prediction system is based on more than two decades of expertise in AI and has been trained on proprietary immune data, allowing it to accurately prioritize and select the most immunogenic sequences.
To evaluate the accuracy of the prediction, samples from cancer patients were collected. Healthy and tumor tissue were sequenced, and mutations were identified and ranked using the algorithm. These were then evaluated by measuring the frequency of T cells against the predicted antigens. Although preliminary, the results generated to-date suggest that the system can identify rare immunogenic mutation among a large list of candidates identified in the patients.
Transgene uses its expertise in viral vectorization to incorporate the selected neoantigen sequences in the genome of the Modified Vaccinia virus Ankara (MVA) viral vector. The Company has set up a unique in-house good manufacturing practice (GMP) unit dedicated to manufacturing the individualized batches of TG4050 needed for the clinical development of this novel individualized therapeutic vaccine.
Title of the poster: Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine
Authors: Brandon Malone, Caroline Tosch, Benoit Grellier, Kousuke Onoue, Timo Sztyler, Karola Rittner, Yoshiko Yamashita, Eric Quemeneur, Kaidre Bendjama
Session Date and Time: June 22-24, 2020
Abstract/Poster Number: 4566
The abstract can be downloaded on the AACR website.
About 4050
TG4050 is an individualized immunotherapy being developed for solid tumors that is based on Transgene's myvac technology and powered by NEC's longstanding artificial intelligence (AI) expertise. This virus-based therapeutic vaccine encodes neoantigens (patient-specific mutations) identified and selected by NEC's Neoantigen Prediction System. The prediction system is based on more than two decades of expertise in AI and has been trained on proprietary data allowing it to accurately prioritize and select the most immunogenic sequences.
TG4050 is designed to stimulate the immune system of patients in order to induce a T-cell response that is able to recognize and destroy tumor cells based on their own neoantigens. This individualized immunotherapy is developed for each patient and can be produced in a very short time frame.
This best-in-class candidate is being evaluated in two Phase 1 clinical trials for patients with ovarian cancers (NCT03839524) and HPV-negative head and neck cancers (NCT04183166).
About myvac
myvac is a viral vector (MVA) based, individualized immunotherapy platform that has been developed by Transgene to target solid tumors. myvac-derived products are designed to stimulate the patient's immune system to recognize and destroy tumors using the patient's own cancer-specific genetic mutations. Transgene has set up an innovative network to support the development of myvac individualized immunotherapies that combines bioengineering, digital transformation, established vectorization know-how and unique manufacturing capabilities. Transgene has been awarded an "Investment for the Future" funding from Bpifrance for the development of its platform myvac. TG4050, the first myvac-derived product, is currently being evaluated in two solid tumor clinical trials.
About NEC's Neoantigen Prediction System
NEC's neoantigen prediction utilizes its proprietary artificial intelligence (AI), such as graph-based relational learning, which is combined with other sources of data to discover candidate neoantigen targets. NEC comprehensively evaluates the candidate neoantigens, with a primary focus placed on its in-house major histocompatibility complex (MHC) binding affinity prediction trained on public and proprietary datasets. These allow NEC to effectively prioritize the numerous candidate neoantigens identified in a single patient.
About Transgene
Transgene (Euronext: TNG) is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.
The Company's clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO platform).
With Transgene's myvac platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac approach allows the generation of virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO collaboration with AstraZeneca.
Additional information about Transgene is available at: https://www.transgene.fr/.
Follow us on Twitter: @TransgeneSA
About NEC Corporation
NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com.For additional information, please also visit NEC Laboratories Europe GmbH at: http://www.neclab.eu
Topic: Press release summary
Source: NEC Corporation
Sectors: BioTech, Artificial Intel [AI]
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| |
| NEC Corporation Related News |
|
| Thursday, 19 December 2024, 12:02 JST |
| NEC Completes new Asia Pacific submarine cable |
|
| Wednesday, 18 December 2024, 17:12 JST |
| NEC Receives Telecom Review's Global Excellence Award for Innovative Telecom B2B/ Enterprise Network Solutions |
|
| Thursday, 12 December 2024, 16:27 JST |
| NEC Announces Interim Results from Phase 1 Clinical Trial of NECVAX-NEO1, an AI-Driven Personalized Oral Cancer Vaccine, at ESMO Immuno-Oncology Congress 2024 |
|
| Monday, 9 December 2024, 14:06 JST |
| NEC begins sale of 100G QSFP28 ZR4 single-fiber bi-directional optical transceiver |
|
| Friday, 29 November 2024, 15:27 JST |
| JAL and NEC Test AI-Powered Carry-On Baggage Analysis Solution |
|
| More news >> |
|
|
|
